# Automated editorial proposal

- Proposal ID: proposal:5b12c41974c1da31e100f410bfd48611
- Substance: galantamine
- Suggestion type: new-effect
- Source: [Towards Greener Pastures in Alzheimer's Therapy: Synthesis and XRD/HSA/DFT Mechanistic Investigation of Novel Trifluoromethylated Compounds.](https://pubmed.ncbi.nlm.nih.gov/42956264/)
- PMID: 42956264
- DOI: 10.1002/ardp.70375
- Published: 2026-11-01
- Journal: not stated

This file is a review proposal. It is not a published BHWiki article and must not be treated as medical guidance.

## Embedded source snapshot

This abstract snapshot is included so an offline reviewer can check abstract-level claims. It is not a substitute for full-text, version, retraction or licensing verification.

### Abstract

> A concise, high-yield one-pot protocol afforded two novel trifluoromethylated Schiff base hybrids, (E)-2,2,2-trifluoro-N-(2-((2-hydroxybenzylidene)amino)-2-methylpropyl)acetamide (1) and its 2-hydroxynaphthyl analogue (2). Both combine a branched diamine core, a phenolic/naphtholic imine, and a trifluoroacetamide fragment, giving fluorinated frameworks distinct from reported donepezil and galantamine analogues, which typically use extended benzyl-piperidine architectures. Both compounds were characterised by multinuclear NMR, IR, MS and elemental analysis; their purity was established by reverse-phase HPLC (98.8% for 1 and > 99% for 2 after recrystallisation), and their structures were determined by single-crystal X-ray diffraction. Crystal structure and Hirshfeld surface analyses reveal a tautomerism-controlled switch in supramolecular assembly: compound 1 adopts an enol-imine form, generating discrete amide-phenol dimers via a robust heterosynthon, while 2 exists as a keto-enamine, forming infinite N-H···O hydrogen-bonded chains reinforced by π-π stacking of naphthalene rings. DFT calculations (B3LYP/6-311 + G(d,p)) support these findings, showing distinct charge distributions and a reduced HOMO-LUMO gap for 2, consistent with enhanced electronic polarizability. Molecular docking against acetylcholinesterase (PDB: 1EVE) predicted that both compounds adopt binding modes within the catalytic gorge, with 2 showing particularly favourable interactions within the catalytic gorge. These predictions were tested experimentally. In a colorimetric AChE inhibitor screening assay both compounds inhibit the enzyme in a concentration-dependent manner, with IC<sub>50</sub> values of 22.5 µM (1) and 55.0 µM (2) against 15.0 µM for the galantamine reference measured alongside. Compound 1 is the more potent of the pair, by a factor of 2.4, and comes within 1.5-fold of the reference inhibitor, identifying the compact phenolic scaffold rather than the extended naphthalenic one as the better lead for further development. Computational ADME/Tox profiling tentatively predicts compliance with Lipinski and Veber criteria, oral bioavailability, blood-brain barrier permeation, and acceptable toxicity classes, pending experimental confirmation. Overall, this work establishes a synthetically accessible, structurally tunable family of trifluoromethylated scaffolds whose solid-state behaviour and preliminary computational pharmacology indicate potential as crystallography-guided AChE inhibitor candidates warranting further investigation.

## Proposed structured change

```json
{
  "effect": "acetylcholinesterase inhibition",
  "value": "IC50 15.0 µM",
  "assay": "colorimetric AChE inhibitor screening assay",
  "context": "galantamine reference measured alongside the test compounds"
}
```

## Model rationale

The abstract reports a galantamine reference IC50 in a colorimetric acetylcholinesterase inhibitor screening assay.

## Verbatim evidence from the abstract

> with IC<sub>50</sub> values of 22.5 µM (1) and 55.0 µM (2) against 15.0 µM for the galantamine reference measured alongside.

## Human review

- [ ] Open the canonical publication and inspect the strongest permitted full text.
- [ ] Verify article version, retraction/correction state, population, exposure, comparator, outcome and limitations.
- [ ] Verify funding/conflict and reuse rights; remove any unsupported field.
- [ ] Apply changes manually to the appropriate Markdown source; do not edit this proposal into public content.
- [ ] Run `bun run content:validate`, `bun run test`, and the normal publisher before merging.
